ABVC BioPharma Inc (NASDAQ: ABVC) is a clinical-stage biopharmaceutical company that develops drug and therapeutic product candidates through collaborative agreements with partners. Revenue is generated through a combination of non-refundable upfront license fees, milestone payments tied to development and regulatory events, and royalty or profit-sharing arrangements with collaboration partners, as disclosed in the FY2025 10-K filed March 3, 2026. The company operates through subsidiaries including BioKey, Inc. (a California corporation providing CDMO services such as formulation development, IND/NDA/ANDA submissions, and clinical trial manufacturing), BioLite Holding, Inc. (a Nevada corporation), and American BriVision Corporation (a Delaware corporation). ABVC holds a 37% ownership stake in Rgene Corporation as of April 2025, following conversion of a convertible loan originated in 2022. The company also maintains a collaborative agreement with BioFirst Corporation, a related party. As of December 31, 2025, cash and cash equivalents exceeded FDIC insurance limits by approximately $265,521.

Revenue model

Non-refundable upfront license fees recognized upon transfer of intellectual property licenses to collaboration partners; contingent milestone payments based on development, regulatory, and commercial events; and royalty and profit-sharing payments from collaboration partners. BioKey also generates revenue through CDMO services including formulation development, stability studies, regulatory submissions, and clinical trial material manufacturing.

Products and services

Drug and therapeutic product candidates in clinical development; CDMO services through BioKey including API characterization, pre-formulation studies, formulation development, analytical method development, stability studies, IND/NDA/ANDA/510K submissions, and manufacturing of clinical trial materials through Phase III and commercial manufacturing.

Customers and end markets

Collaboration partners who license ABVC intellectual property and fund milestone-based development programs. CDMO customers who require contract pharmaceutical development and manufacturing services. Specific customer names and concentration percentages are referenced in the filing but not fully disclosed in the available excerpts.

Value-chain role

Clinical-stage drug developer and CDMO service provider. ABVC sits between early-stage research and commercial manufacturing, licensing IP to collaboration partners and providing development and manufacturing services through BioKey. Holds minority equity stakes in related parties Rgene Corporation (37% as of April 2025) and operates under a service agreement with Rgene tied to patent expiration.

Geographic exposure

Operations in the United States (California) and Taiwan. Cash deposits held at institutions subject to Taiwan Central Deposit Insurance Corporation coverage (NTD 3.0 million limit, equivalent to approximately $95,400) and U.S. FDIC coverage ($250,000 limit). Subsidiaries incorporated in California, Nevada, Delaware, British Virgin Islands, and Cayman Islands.

Source: SEC 10-K, filed 2026-03-03

Industry: Pharmaceutical Preparations Peers: AIM ImmunoTech Inc Ainos Inc Neurogene Inc Aravive, Inc. Oruka Therapeutics Inc Avalo Therapeutics Inc Codiak BioSciences, Inc. Harpoon Therapeutics, Inc. Maia Biotechnology Inc